Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma

David A. Rodeberg, Rebecca A. Nuss, Carrie J. Heppelmann, Esteban Celis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Alveolar rhabdomyosarcoma (ARMS) frequently contains the fusion transcription factor PAX3/FKHR. Therefore, clinical studies have been initiated to utilize the PAX3/FKHR translocation point area as a peptide vaccine against ARMS. Our study was directed at identifying antigenic T-lymphocyte epitopes at the PAX3/FKHR translocation point area. Experimental design: The peptide sequence surrounding the PAX3/FKHR translocation point was evaluated by MHC binding algorithms for potential T-lymphocyte antigenic epitopes (class I molecules HLA-A1, -A2 and -A3; class II molecules HLA-DR1, -DR4 and -DR7). Using in vitro techniques, dendritic cells loaded with PAX3/FKHR peptides were used to stimulate naïve T-lymphocytes. T-lymphocyte activity was then evaluated by 51Cr release and 3H-thymidine uptake assays. Results: Only one HLA-A3-restricted epitope was predicted by the algorithms. The peptide was prepared and tested for its ability to stimulate naïve cytotoxic T-lymphocytes (CTLs). Unfortunately, the peptide was unsuccessful at stimulating naïve CTL. However, induction of naïve helper T-lymphocytes (HTL) to recognize and respond to the PAX3/FKHR translocation peptide was successful. Yet, this HTL peptide activity did not translate into recognition of PAX3/FKHR-containing ARMS tumor cells. Conclusions: It appears that the fusion area of PAX3/FKHR may not be a good source of antigenic anti-tumor peptide epitopes. These results raise serious concerns about the success and applicability of future peptide-based vaccine immunotherapy directed at the PAX3/FKHR translocation point.

Original languageEnglish (US)
Pages (from-to)526-534
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume54
Issue number6
DOIs
StatePublished - Jun 1 2005

Fingerprint

Alveolar Rhabdomyosarcoma
T-Lymphocytes
Peptides
Subunit Vaccines
T-Lymphocyte Epitopes
Cytotoxic T-Lymphocytes
Helper-Inducer T-Lymphocytes
Epitopes
HLA-A3 Antigen
HLA-DR1 Antigen
HLA-A1 Antigen
HLA-DR4 Antigen
HLA-A2 Antigen
Immunotherapy
Dendritic Cells
Thymidine
Neoplasms
Research Design

Keywords

  • Cancer vaccine
  • Cytotoxic T-lymphocyte
  • Dendritic cell
  • Helper T-lymphocyte
  • Peptide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma. / Rodeberg, David A.; Nuss, Rebecca A.; Heppelmann, Carrie J.; Celis, Esteban.

In: Cancer Immunology, Immunotherapy, Vol. 54, No. 6, 01.06.2005, p. 526-534.

Research output: Contribution to journalArticle

Rodeberg, David A. ; Nuss, Rebecca A. ; Heppelmann, Carrie J. ; Celis, Esteban. / Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma. In: Cancer Immunology, Immunotherapy. 2005 ; Vol. 54, No. 6. pp. 526-534.
@article{87ea39d1b8cb468597f70b5b8a4eb286,
title = "Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma",
abstract = "Purpose: Alveolar rhabdomyosarcoma (ARMS) frequently contains the fusion transcription factor PAX3/FKHR. Therefore, clinical studies have been initiated to utilize the PAX3/FKHR translocation point area as a peptide vaccine against ARMS. Our study was directed at identifying antigenic T-lymphocyte epitopes at the PAX3/FKHR translocation point area. Experimental design: The peptide sequence surrounding the PAX3/FKHR translocation point was evaluated by MHC binding algorithms for potential T-lymphocyte antigenic epitopes (class I molecules HLA-A1, -A2 and -A3; class II molecules HLA-DR1, -DR4 and -DR7). Using in vitro techniques, dendritic cells loaded with PAX3/FKHR peptides were used to stimulate na{\"i}ve T-lymphocytes. T-lymphocyte activity was then evaluated by 51Cr release and 3H-thymidine uptake assays. Results: Only one HLA-A3-restricted epitope was predicted by the algorithms. The peptide was prepared and tested for its ability to stimulate na{\"i}ve cytotoxic T-lymphocytes (CTLs). Unfortunately, the peptide was unsuccessful at stimulating na{\"i}ve CTL. However, induction of na{\"i}ve helper T-lymphocytes (HTL) to recognize and respond to the PAX3/FKHR translocation peptide was successful. Yet, this HTL peptide activity did not translate into recognition of PAX3/FKHR-containing ARMS tumor cells. Conclusions: It appears that the fusion area of PAX3/FKHR may not be a good source of antigenic anti-tumor peptide epitopes. These results raise serious concerns about the success and applicability of future peptide-based vaccine immunotherapy directed at the PAX3/FKHR translocation point.",
keywords = "Cancer vaccine, Cytotoxic T-lymphocyte, Dendritic cell, Helper T-lymphocyte, Peptide",
author = "Rodeberg, {David A.} and Nuss, {Rebecca A.} and Heppelmann, {Carrie J.} and Esteban Celis",
year = "2005",
month = "6",
day = "1",
doi = "10.1007/s00262-004-0625-6",
language = "English (US)",
volume = "54",
pages = "526--534",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma

AU - Rodeberg, David A.

AU - Nuss, Rebecca A.

AU - Heppelmann, Carrie J.

AU - Celis, Esteban

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Purpose: Alveolar rhabdomyosarcoma (ARMS) frequently contains the fusion transcription factor PAX3/FKHR. Therefore, clinical studies have been initiated to utilize the PAX3/FKHR translocation point area as a peptide vaccine against ARMS. Our study was directed at identifying antigenic T-lymphocyte epitopes at the PAX3/FKHR translocation point area. Experimental design: The peptide sequence surrounding the PAX3/FKHR translocation point was evaluated by MHC binding algorithms for potential T-lymphocyte antigenic epitopes (class I molecules HLA-A1, -A2 and -A3; class II molecules HLA-DR1, -DR4 and -DR7). Using in vitro techniques, dendritic cells loaded with PAX3/FKHR peptides were used to stimulate naïve T-lymphocytes. T-lymphocyte activity was then evaluated by 51Cr release and 3H-thymidine uptake assays. Results: Only one HLA-A3-restricted epitope was predicted by the algorithms. The peptide was prepared and tested for its ability to stimulate naïve cytotoxic T-lymphocytes (CTLs). Unfortunately, the peptide was unsuccessful at stimulating naïve CTL. However, induction of naïve helper T-lymphocytes (HTL) to recognize and respond to the PAX3/FKHR translocation peptide was successful. Yet, this HTL peptide activity did not translate into recognition of PAX3/FKHR-containing ARMS tumor cells. Conclusions: It appears that the fusion area of PAX3/FKHR may not be a good source of antigenic anti-tumor peptide epitopes. These results raise serious concerns about the success and applicability of future peptide-based vaccine immunotherapy directed at the PAX3/FKHR translocation point.

AB - Purpose: Alveolar rhabdomyosarcoma (ARMS) frequently contains the fusion transcription factor PAX3/FKHR. Therefore, clinical studies have been initiated to utilize the PAX3/FKHR translocation point area as a peptide vaccine against ARMS. Our study was directed at identifying antigenic T-lymphocyte epitopes at the PAX3/FKHR translocation point area. Experimental design: The peptide sequence surrounding the PAX3/FKHR translocation point was evaluated by MHC binding algorithms for potential T-lymphocyte antigenic epitopes (class I molecules HLA-A1, -A2 and -A3; class II molecules HLA-DR1, -DR4 and -DR7). Using in vitro techniques, dendritic cells loaded with PAX3/FKHR peptides were used to stimulate naïve T-lymphocytes. T-lymphocyte activity was then evaluated by 51Cr release and 3H-thymidine uptake assays. Results: Only one HLA-A3-restricted epitope was predicted by the algorithms. The peptide was prepared and tested for its ability to stimulate naïve cytotoxic T-lymphocytes (CTLs). Unfortunately, the peptide was unsuccessful at stimulating naïve CTL. However, induction of naïve helper T-lymphocytes (HTL) to recognize and respond to the PAX3/FKHR translocation peptide was successful. Yet, this HTL peptide activity did not translate into recognition of PAX3/FKHR-containing ARMS tumor cells. Conclusions: It appears that the fusion area of PAX3/FKHR may not be a good source of antigenic anti-tumor peptide epitopes. These results raise serious concerns about the success and applicability of future peptide-based vaccine immunotherapy directed at the PAX3/FKHR translocation point.

KW - Cancer vaccine

KW - Cytotoxic T-lymphocyte

KW - Dendritic cell

KW - Helper T-lymphocyte

KW - Peptide

UR - http://www.scopus.com/inward/record.url?scp=18044369834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044369834&partnerID=8YFLogxK

U2 - 10.1007/s00262-004-0625-6

DO - 10.1007/s00262-004-0625-6

M3 - Article

VL - 54

SP - 526

EP - 534

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -